China Medical University Hospital

Seoul National University Bundang Hospital in Seoul, South Korea has been recently validated for Stage 6 of the classic HIMSS Analytics Maturity Assessment Model . AMAM measures an organisation's capabilities and advances in healthcare analytics. A new, modernised version of this model – dubbed AMAM24 – was launched at the recently concluded HIMSS24 APAC conference. WHY IT MATTERS SNUBH credits its latest achievement to its prior experience getting validated four times for Stage 7 of the HIMSS Electronic Medical Record Adoption Model . Its Data Convergence Team under the Office of Hospital Information led this process and ensured close collaboration between the medical informatics and hospital operation teams. One of the highlights of the validation is the CDW 3.0, an upgraded version of a clinical data warehouse that the hospital had used for a decade. SNUBH embarked on this upgrade two years ago to create "an advanced, open-source data warehouse equipped with machine learning capabilities." Following the launch of the CDW 3.0 in October last year, SNUBH staff reported an increase in data retrieval and analysis speeds with the use of the system. The CDW now has a user-friendly interface that allows step-by-step patient cohort definition. It also streamlines data visualisation; enhances data security with masking and anonymisation modules; standardises unstructured data and aligns with international standard codes; and provides a single source of learning resources, including pre-defined datasets for ML/AI research. In their validation, HIMSS noted that the consolidated CDW was "accessible, convenient, and user-friendly." "This makes it a tremendously powerful tool for executives and clinicians to view, understand and analyse data, and generate insights to improve clinical care and organisational performance," Andrew Pearce, HIMSS VP Analytics and Global Advisory Lead, commented. Validators also commended SNUBH for tracking and reporting over 200 indicators via several dashboards. An example of this is the dashboard for the Rapid Response System (RRS). The hospital first set up the RRS in 2012 to resolve usual delays in responding to patient deterioration. Now in its second phase of implementation, the RRS operates round-the-clock with 15 nurses. The hospital observed a "significant decrease" in cardiopulmonary resuscitation events in the general wards over a decade since the system was first activated. Another notable improvement is the RRS dashboard facilitating a prompt transfer of patients to the ICU. In addition, SNUBH demonstrated during its AMAM validation the implementation of an AI-based ECG interpretation tool on its HIS, which is now used to generate quantitative risk assessments of cardiac events and assist with diagnosing arrhythmias and other related emergency conditions. The project aims to address delays in detecting cardiac issues and enable the creation of personalised treatment plans. Based on a test pilot prior to its initial integration in April this year, the AI tool showed proficiency in rhythm analysis and classification of 10 identified digital biomarkers. Following clinical integration, SNUBH clinicians highlighted the tool's ability to diagnose severe hyperkalemia early. Evaluation studies are ongoing to further prove its effectiveness. After this AMAM validation, SNUBH is moving on with plans to strengthen its enterprise data warehouse and improve its operational data analysis capabilities, focusing on post-monitoring systems to incorporate the analytical life cycle – which is now part of the modernised AMAM. THE LARGER TREND Fellow Korean hospital, Samsung Medical Center , became the first hospital in Asia-Pacific to get validated for Stage 7 of the HIMSS AMAM in May. It was also the first in the region to achieve Stage 6 last year. Outside South Korea, China Medical University Hospital of Taiwan is also currently validated for Stage 6 HIMSS AMAM. Meanwhile, SNUBH underwent its fourth validation for the HIMSS EMRAM late last year. The hospital was the first outside the United States to be validated for Stage 7 of this model in 2010. ON THE RECORD "SNUBH has consistently built its data analysis capabilities, which have been progressively validated through our previous four EMRAM certifications. I am delighted that we have once again affirmed our data analysis competency through this AMAM Stage 6 certification. This achievement not only recognises our current capabilities but also sets the stage for our continued advancement in leveraging data for improved healthcare delivery and operational excellence," Dr Junghan Song, president and CEO of SNUBH, said in a statement. "We specifically chose HIMSS AMAM validation to strengthen our data-driven decision-making abilities and evaluate the current state of our data-related platforms. SNUBH has evolved alongside HIMSS certifications, and we are committed to continuing this journey into the future. As highlighted at HIMSS APAC 2024, the newly modernised AMAM validation is well-designed. Through this framework, we once again aim to drive innovation in data-driven decision-making across both our clinical and operational domains," Dr Seyoung Jung, CIO of SNUBH, also commented.

TAICHUNG, Oct. 10, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH, Taiwan) continues to make significant strides in cell therapy, demonstrating its leadership on the global stage. Ms. Lin, a patient with malignant glioma, underwent tumor removal surgery followed by radiation therapy and dendritic cell immunotherapy. After four years of follow-up, her condition remains stable, and she maintains an excellent quality of life. Continue Reading Dr. Chen Chun-Chung (right), Chief of CMUH’s Neurosurgery Department, representing the Taiwan Neurosurgical Society, signed an MOU with Prof. Dato Dr. Abdul Rahman Izaini Ghani, President of the Neurosurgical Association of Malaysia, in Kuching, Malaysia. This agreement makes a significant milestone in neurosurgical collaboration between Taiwan and Malaysia, offering Malaysian neurosurgeons streamlined access to Taiwan’s advanced medical technologies. "Malignant gliomas are notoriously challenging to treat," said Dr. Chen Chun-Chung, Director of Neurosurgery at CMUH. "Thanks to Ms. Lin's positive attitude and the advanced cell therapy, we've achieved promising outcomes." On September 14, three CMUH physicians were invited to speak at the Sarawak Neurosurgery Update & Neurosurgical Association of Malaysia Annual Scientific Meeting 2024 (NAM-SNU ASM 2024). Dr. Chen Chun-Chung highlighted the success of CMUH's cell therapy, while representatives from the Taiwanese and Malaysian Neurosurgical Societies signed a Memorandum of Understanding (MOU), strengthening medical exchange and collaboration between the two countries. Taiwan's First Participation in NAM-SNU ASM: A Milestone in Taiwan-Malaysia Medical Exchange Following the successful "Taiwan-Malaysia Neurosurgery Advanced Medical Summit 2024" in July, Taiwan made its debut participation at NAM-SNU ASM 2024. Dr. Chen Chun-Chung, alongside Dr. Brian Chiu Cheng-Di, Director of Minimally Invasive Spine Neurosurgery, and Dr. Chuang Hao-Yu, Director of the Cell Therapy Center at Tainan City An Nan Hospital, were invited to present at the conference. This marked the first time Taiwanese physicians participated in the event. The MOU signed between the Taiwan Neurosurgical Society (TNS) and the Neurosurgical Association of Malaysia (NAM) is seen as a key development in Taiwan-Malaysia neurosurgical collaboration. Cutting-edge Neurosurgical Techniques Spark Interest from Malaysian Physicians At CMUH physicians presented on cutting-edge neurosurgical techniques, including treatments for brain cancer, stroke, and endoscopic spine surgery. Their presentations attracted significant attention and sparked enthusiastic discussions among conference attendees. Dr. Chen shared the success story of Ms. Lin, diagnosed with malignant glioma in 2000 after experiencing seizures. Despite the challenges of treating this aggressive brain cancer, Ms. Lin underwent surgery, radiation therapy, and dendritic cell immunotherapy, receiving ten vaccine injections. Her progress has been closely monitored for over four years, showing significant improvement. Dr. Chen highlighted those traditional treatments for malignant glioma, primarily radiation and limited targeted therapies, offer an average survival rate of just 15 months. However, at CMUH, the average survival has risen to 23 months, with Ms. Lin surpassing the four-year milestone. CMUH's cell therapy program is now advancing into CAR-T cell therapy, promising even better outcomes for cancer patients. "We are excited to share our clinical experience in cell therapy with our Malaysian colleagues and continue to promote the exchange of medical expertise," said Dr. Chen. Dr. Brian Chiu Cheng-Di highlighted Taiwan's extensive clinical experience in endoscopic spine surgery, which allows for minimally invasive procedures with faster recovery times. The technique is especially beneficial for spinal disc removal, spinal stenosis, and tumor surgeries, though more careful assessment is required for cases involving structural abnormalities or malignancies. Following Dr. Chiu's presentation, three Malaysian experts signed up for advanced training in Taiwan. Dr. Chuang Hao-Yu presented on two key areas of Taiwan's neurosurgery advancements. The first focused on intracerebral hemorrhagic stroke, which has a higher incidence in Asia than in Western countries, and how Taiwan's minimally invasive surgery techniques significantly reduce mortality and neurological disabilities. The second highlighted Taiwan's progress in interventional vascular treatments, developed through collaborative efforts of six major medical societies. Strengthening Taiwan-Malaysia Medical Cooperation Chou Aichi, CEO of CMUH's International Center, emphasized that neurosurgery has been a focal point for Taiwan-Malaysia medical exchanges for the past three years under the Ministry of Health and Welfare's "New Southbound Medical and Health Cooperation and Industry Development" initiative. The partnership includes seminars, hospital visits, health lectures, and physician training in Taiwan. At this year's conference, Taiwanese companies Brain Navi Biotechnology and EPED Inc. showcased Taiwan's cutting-edge medical technologies. The MOU signed between TNS and NAM strengthens opportunities for Malaysian neurosurgeons to benefit from Taiwan's advanced innovations. This collaboration marks a significant milestone in Taiwan's New Southbound Policy, further promoting medical partnerships across Southeast Asia. Contact: Carolyn Chen [email protected] SOURCE China Medical University Hospital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Security concerns and vendor restrictions are some of the major barriers to unlocking health data's full potential in raising patient outcomes. In the HIMSS24 APAC plenary session, "Power of Data in Modern Healthcare," Cho Chi-Heum, professor and president of Keimyung University Dongsan Medical Center in South Korea, and Dr Shih-Sheng Chang, director of the Artificial Intelligence Center at China Medical University Hospital (CMUH) in Taiwan, discussed challenges in data integration and interoperability. To allow their doctors to securely share patient data, Keimyung Hospital has in place an ISM (information security management) system, which is at the core of its data privacy and security strategy. "We strictly follow personal information protection guidelines also," added Prof Cho. Common vendor arrangements also hinder hospitals from generating valuable insights from comprehensive, integrated data. Some vendors may allow multi-source data integrations, but this usually comes with hefty costs due to proprietary data usage rights, noted Dr Chang. "Sometimes, they will provide very fancy software which includes [all] data, but we cannot pay for each." Dr Chang and his team have learned to approach this problem by taking this initial step: "If we want to set up a new machine or a new modality, we will ask the vendor, 'Can you share the data with us? Otherwise, we will consider another vendor.'" Driving efficiencies The two speakers also discussed how their clinicians have wasted time doing tedious administrative tasks. "Most doctors in Korea just always look at their computers. They are so busy [with their computers] that they cannot [meet] their patients… I don't wish to see this kind of hospital," Prof Cho shared. Nurses, meanwhile, spend 60% of their time doing repetitive tasks, particularly checking patients' vital signs. "This is very repeated and [mechanical]." According to Prof Cho, Keimyung Hospital is looking to implement wearable devices as part of remote patient monitoring to help nurses save time. Meanwhile, as part of its data quality management – and by extension, AI development, CMUH is also considering large language models (LLM) to build a system for structured data. Through LLMs, Dr Chang said, clinicians would not have to create structured clinical reports, which may take up to 30 minutes each. Prof Cho however cautions against over-relying on computer software, particularly those running on AI. "We are human beings. We are not AI; we are just using AI." At Keimyung Hospital, he envisions an "emotional hospital" that prioritises meeting patients eye-to-eye. "AI cannot replace the human. But it can [help] save time to let us have [that] eye contact with our patients," Dr Chang said, echoing Prof Cho's statement.